The World Anti-Doping Agency (WADA) has put peptides squarely in its sights. The newly released 2027 Prohibited List was approved by the Executive Committee on Thursday 10 September 2026 and takes effect on Friday 01 January 2027.
According to the U.S. Anti-Doping Agency (USADA), the update is minor overall, but peptides are now explicitly identified as prohibited under class S0, which covers non-approved substances banned at all times. BPC-157, TB-500, AOD-9604, ipamorelin, MK-677 and CJC-1295 remain listed examples. USADA warns that unlisted, renamed or experimental peptides may also be prohibited, and athletes remain strictly liable for all substances found in their bodies.
The timing matters for amateur athletes. As we reported in July 2026, a U.S. Food and Drug Administration (FDA) advisory panel recommended broader access to BPC-157 and TB-500, among other substances.
On Thursday, the FDA submitted an interim access policy for compounded pharmacies to make peptides for White House review. If approved, the policy would make peptides easier to obtain, but it would not change the rules for competitive athletes: a prescription does not make a prohibited substance permissible in sport.
We also reported on the four-year ban imposed on triathlete and coach Anthony McCauley for administering peptides to athletes.
Cycling has its own warning. South African rider S’annara Grove was provisionally suspended after an out-of-competition sample collected on Tuesday 28 July 2026 returned a finding of ipamorelin, according to the International Testing Agency. This appears to be the first reported ipamorelin positive at the professional level. A provisional suspension is not a final ruling.
GLP-1 drugs semaglutide and tirzepatide remain permitted and are not on the Prohibited List, but are now included in WADA’s monitoring programme.
The advice is simple: check GlobalDRO.com before taking any medication or supplement.
© 2026 Copyright Gran Fondo Daily News – All Rights Reserved